Literature DB >> 24525638

Failed response to repeat intravenous ketamine infusions in geriatric patients with major depressive disorder.

Sarah M Szymkowicz1, Nora Finnegan, Roman M Dale.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24525638      PMCID： PMC3941032          DOI： 10.1097/JCP.0000000000000090

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  15 in total

1.  The use of a series of ketamine infusions in two patients with treatment-resistant depression.

Authors:  Michael Messer; Irina V Haller; Pamela Larson; Julia Pattison-Crisostomo; Charles E Gessert
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2010       Impact factor: 2.198

2.  Changes in anesthetic sensitivity and glutamate receptors in the aging canine brain.

Authors:  K R Magnusson; C Scanga; A E Wagner; C Dunlop
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2000-09       Impact factor: 6.053

Review 3.  Comorbidity of depression and anxiety in the elderly.

Authors:  Eric J Lenze
Journal:  Curr Psychiatry Rep       Date:  2003-05       Impact factor: 5.285

4.  Antidepressant effects of ketamine in depressed patients.

Authors:  R M Berman; A Cappiello; A Anand; D A Oren; G R Heninger; D S Charney; J H Krystal
Journal:  Biol Psychiatry       Date:  2000-02-15       Impact factor: 13.382

Review 5.  Ketamine as a novel antidepressant: from synapse to behavior.

Authors:  J W Murrough
Journal:  Clin Pharmacol Ther       Date:  2011-12-28       Impact factor: 6.875

6.  Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression.

Authors:  Hiroyuki Koike; Michihiko Iijima; Shigeyuki Chaki
Journal:  Behav Brain Res       Date:  2011-06-06       Impact factor: 3.332

7.  Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

Authors:  James W Murrough; Andrew M Perez; Sarah Pillemer; Jessica Stern; Michael K Parides; Marije aan het Rot; Katherine A Collins; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu
Journal:  Biol Psychiatry       Date:  2012-07-27       Impact factor: 13.382

8.  Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

Authors:  Marije aan het Rot; Katherine A Collins; James W Murrough; Andrew M Perez; David L Reich; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

9.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

10.  A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression.

Authors:  Sarah M Szymkowicz; Nora Finnegan; Roman M Dale
Journal:  J Affect Disord       Date:  2012-11-22       Impact factor: 4.839
View more
  9 in total

Review 1.  Use of Ketamine in Elderly Patients with Treatment-Resistant Depression.

Authors:  Carolina Medeiros da Frota Ribeiro; Patricio Riva-Posse
Journal:  Curr Psychiatry Rep       Date:  2017-11-15       Impact factor: 5.285

2.  Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study.

Authors:  Alina Wilkowska; Adam Włodarczyk; Maria Gałuszko-Węgielnik; Mariusz S Wiglusz; Wiesław J Cubała
Journal:  Neuropsychiatr Dis Treat       Date:  2021-08-14       Impact factor: 2.570

3.  Effect of Ketamine, Thiopental and Ketamine-Thiopental Combination during Electroconvulsive Therapy for Depression.

Authors:  Özlem Özkan Kuşçu; Feride Karacaer; Ebru Biricik; Ersel Güleç; Lut Tamam; Yasemin Güneş
Journal:  Turk J Anaesthesiol Reanim       Date:  2015-08-21

4.  Age affects temporal response, but not durability, to serial ketamine infusions for treatment refractory depression.

Authors:  Steven Pennybaker; Brian J Roach; Susanna L Fryer; Anusha Badathala; Art W Wallace; Daniel H Mathalon; Tobias F Marton
Journal:  Psychopharmacology (Berl)       Date:  2021-08-07       Impact factor: 4.530

5.  Prophylactic (R,S)-Ketamine Is Effective Against Stress-Induced Behaviors in Adolescent but Not Aged Mice.

Authors:  Alessia Mastrodonato; Ina Pavlova; Noelle C Kee; Van Anh Pham; Josephine C McGowan; J John Mann; Christine A Denny
Journal:  Int J Neuropsychopharmacol       Date:  2022-06-21       Impact factor: 5.678

6.  Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.

Authors:  Mark J Niciu; David A Luckenbaugh; Dawn F Ionescu; Erica M Richards; Jennifer L Vande Voort; Elizabeth D Ballard; Nancy E Brutsche; Maura L Furey; Carlos A Zarate
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

7.  Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial.

Authors:  Marijn Lijffijt; Nicholas Murphy; Sidra Iqbal; Charles E Green; Tabish Iqbal; Lee C Chang; Colin N Haile; Lorna C Hirsch; Nithya Ramakrishnan; Dylan A Fall; Alan C Swann; Rayan K Al Jurdi; Sanjay J Mathew
Journal:  Neuropsychopharmacology       Date:  2021-11-27       Impact factor: 8.294

8.  Acute (R,S)-Ketamine Administration Induces Sex-Specific Behavioral Effects in Adolescent but Not Aged Mice.

Authors:  Alessia Mastrodonato; Ina Pavlova; Noelle Kee; Josephine C McGowan; J John Mann; Christine A Denny
Journal:  Front Neurosci       Date:  2022-04-21       Impact factor: 4.677

9.  Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT).

Authors:  Joakim Ekstrand; Christian Fattah; Marcus Persson; Tony Cheng; Pia Nordanskog; Jonas Åkeson; Anders Tingström; Mats B Lindström; Axel Nordenskjöld; Pouya Movahed Rad
Journal:  Int J Neuropsychopharmacol       Date:  2022-05-27       Impact factor: 5.678
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.